



The Medicines Patent Pool Foundation

Board resolution

02 September 2022 (via correspondence)

The Governance Board of the Medicines Patent Pool (MPP) thanks the Expert Advisory Group (EAG) for its report assessing the final results of negotiations between the MPP and Medincell on a licence agreement for long-acting technology for malaria vector control. Having reviewed the EAG Report as well as the proposed licence agreement, the Board agrees with the EAG's assessment that the proposed collaboration is consistent with the MPP's mandate as defined in its statutes, and represents a significant improvement over the status quo.

Therefore, the Board requests the Executive Director to finalise and sign the necessary documents with Medincell to formalise the collaboration.